Today, Analysts Issue Forecasts for Neurocrine Biosciences Inc.’s FY2016 Earnings (NBIX)

Today, Analysts Issue Forecasts for Neurocrine Biosciences Inc.’s FY2016 Earnings (NBIX)
Neurocrine Biosciences Inc. (NASDAQ:NBIX) – Research analysts at Oppenheimer Holdings issued their FY2016 earnings per share estimates for Neurocrine Biosciences in a report issued on Monday. Oppenheimer Holdings analyst J. Olson anticipates that the firm will post earnings per share of ($1.65) for the year. Oppenheimer Holdings has a “Market Perform” rating and a $55.00 price target on the stock. Oppenheimer Holdings also issued estimates for Neurocrine Biosciences’ Q1 2017 earnings at ($0.53) EPS, Q3 2017 earnings at $0.54 EPS, Q4 2017 earnings at ($0.27) EPS and FY2017 earnings at ($0.78) EPS.

NBIX has been the topic of a number of other reports. Jefferies Group reiterated a “buy” rating and set a $61.00 price target on shares of Neurocrine Biosciences in a research note on Friday, September 23rd. BMO Capital Markets reiterated an “outperform” rating and set a $66.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, October 13th. Piper Jaffray Cos. reiterated an “overweight” rating and set a $96.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, September 22nd. Robert W. Baird reissued an “outperform” rating and set a $66.00 price objective on shares of Neurocrine Biosciences in a research report on Tuesday, August 30th. Finally, Leerink Swann reissued an “outperform” rating and set a $70.00 price objective on shares of Neurocrine Biosciences in a research report on Wednesday, October 12th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $66.92.

Neurocrine Biosciences (NASDAQ:NBIX) opened at 51.06 on Thursday. The stock’s market capitalization is $4.44 billion. Neurocrine Biosciences has a 52-week low of $31.25 and a 52-week high of $57.82. The firm’s 50-day moving average is $46.81 and its 200-day moving average is $48.15.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Wednesday, November 2nd. The company reported ($0.43) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.14. During the same quarter in the previous year, the business earned ($0.40) EPS. The company’s revenue for the quarter was up .0% on a year-over-year basis.

Several large investors have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD increased its stake in Neurocrine Biosciences by 1.8% in the third quarter. Price T Rowe Associates Inc. MD now owns 9,364,314 shares of the company’s stock valued at $474,209,000 after buying an additional 169,460 shares during the last quarter. Perceptive Advisors LLC increased its stake in Neurocrine Biosciences by 2.8% in the second quarter. Perceptive Advisors LLC now owns 2,797,967 shares of the company’s stock valued at $127,167,000 after buying an additional 77,000 shares during the last quarter. BlackRock Institutional Trust Company N.A. increased its stake in Neurocrine Biosciences by 6.8% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 2,150,949 shares of the company’s stock valued at $108,924,000 after buying an additional 136,277 shares during the last quarter. BlackRock Fund Advisors increased its stake in Neurocrine Biosciences by 3.3% in the third quarter. BlackRock Fund Advisors now owns 2,009,633 shares of the company’s stock valued at $101,768,000 after buying an additional 64,921 shares during the last quarter. Finally, Franklin Resources Inc. increased its stake in Neurocrine Biosciences by 32.8% in the second quarter. Franklin Resources Inc. now owns 1,541,446 shares of the company’s stock valued at $70,059,000 after buying an additional 380,841 shares during the last quarter. 96.30% of the stock is owned by institutional investors and hedge funds.

In related news, insider Malcolm Lloyd-Smith sold 9,000 shares of the company’s stock in a transaction that occurred on Thursday, September 1st. The stock was sold at an average price of $50.00, for a total value of $450,000.00. Following the completion of the transaction, the insider now directly owns 9,000 shares of the company’s stock, valued at $450,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Christopher Flint Obrien sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 15th. The shares were sold at an average price of $52.84, for a total value of $1,321,000.00. Following the completion of the transaction, the insider now directly owns 30,044 shares of the company’s stock, valued at $1,587,524.96. The disclosure for this sale can be found here. 4.80% of the stock is owned by corporate insiders.

About Neurocrine Biosciences

Related posts

Leave a Comment